Hematopoietic progenitors in children with end-stage renal disease.
Bone marrow and circulating erythroid progenitors (BFU-E) in six anemic children with end-stage renal disease (ESRD) were 2.0 and 1.9 times as abundant, respectively, as in six age-matched normal controls and were significantly more responsive in vitro to low concentrations of recombinant human erythropoietin (rHuEpo) than those from the controls. After 4 weeks of rHuEpo therapy, both the number and the in vitro rHuEpo response of circulating BFU-E in the ESRD patients returned to normal control values. The numbers of bone marrow and circulating granulocyte-monocyte progenitors in the ESRD patients before and after rHuEpo therapy were comparable to those of normal controls. There was no inhibition of in vitro erythropoiesis by either the patients' serum or medium conditioned by their mononuclear cells. These results demonstrate a significant abundance and an increased rHuEpo sensitivity of BFU-E in anemic children with ESRD with no evidence of the presence of uremic inhibitors to erythropoiesis.
Barak
Y
Y
Institute for Pediatric Research, Kaplan Hospital, Rehovot, Israel.
Sinai-Treiman
L
L
Karov
Y
Y
Abrahamov
A
A
Drukker
A
A
D000293:Adolescent; D000740:Anemia / Q000097:blood* / Q000628:therapy; D001853:Bone Marrow / Q000473:pathology; D002478:Cells, Cultured; D002648:Child; D017077:Culture Media, Conditioned; D015672:Erythroid Precursor Cells / Q000187:drug effects / Q000473:pathology*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications; D011994:Recombinant Proteins / Q000627:therapeutic use
D017077:Culture Media, Conditioned; D011994:Recombinant Proteins; D004921:Erythropoietin